Since the original ES studies [1,2], inactivating PALB2 mutations were found in small proportions of FPC cohorts (for example, Tischkowitz et al. [4]), and somatic ATM mutations were found in 8% of sporadic pancreatic cancers [5]. Here, PALB2 is linked to pancreatic neoplasm.